Who are DWP14012 Y mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sitagliptin phosphate/metformin hydrochloride FDC, exenatide and sitagliptin, Sitagliptin (Januvia), Sitagliptin + Metformin, SGLT2 inhibitor and DPP-4 inhibitor, Sitagliptin - DPP4i.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dwp14012-y-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DWP14012 Y mg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DWP14012 Y mg (DWP14012 Y mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Endocrinology / Diabetes.

phase 3 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

DWP14012 Y mg (DWP14012 Y mg) — Daewoong Pharmaceutical Co. LTD.. DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DWP14012 Y mg TARGET	DWP14012 Y mg	Daewoong Pharmaceutical Co. LTD.	phase 3	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
Sitagliptin phosphate/metformin hydrochloride FDC	Sitagliptin phosphate/metformin hydrochloride FDC	Merck Sharp & Dohme LLC	marketed	DPP-4 inhibitor / biguanide combination	DPP-4 enzyme / metformin (AMPK pathway)
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
SGLT2 inhibitor and DPP-4 inhibitor	SGLT2 inhibitor and DPP-4 inhibitor	LMC Diabetes & Endocrinology Ltd.	marketed	SGLT2 inhibitor and DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
Sitagliptin - DPP4i	Sitagliptin - DPP4i	Royal Devon and Exeter NHS Foundation Trust	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

Merck Sharp & Dohme LLC · 5 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
LG Life Sciences · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ono Pharmaceutical Co. Ltd · 2 drugs in this class
Cinnagen · 1 drug in this class
GRADE Study Group · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DWP14012 Y mg — Competitive Intelligence Brief. https://druglandscape.com/ci/dwp14012-y-mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing